Skip to content

The effect of orange inhalation aromatherapy on nausea and vomiting

Comparing the effect of orange inhalation aromatherapy and placebo on reducing the severity of nausea and vomiting in pregnant women: A randomized controlled clinical trial.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240809062706N3
Enrollment
88
Registered
2025-10-27
Start date
2025-11-21
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and Vomiting in Pregnancy. Nausea and vomiting

Interventions

Intervention 1: Intervention group: At the start of the intervention, participants will be instructed on how to use the orange essential oil: When feeling nauseous, place two drops of the essential oi

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: primigravida or Multigravida Live and Single Fetus Gestational Age between 8_14 Weeks (with Sonography) Grade of Nausea and Vomiting between 3_12 (Mild and Moderate) Not following a specific anti-nausea diet in the last 24 hours Having at least basic literacy (elementary level) Not using herbal medications simultaneously with the intervention to relieve nausea and vomiting in the last 24 hours Having the possibility of telephone contact No intention to travel within the next 4 days

Exclusion criteria

Exclusion criteria: History of allergy to the studied essential oil Underlying conditions including molar pregnancy, pyelonephritis, thyroid disorders, gastrointestinal diseases, or any other condition causing nausea and vomiting symptoms Multiple pregnancies (e.g., twins or higher-order pregnancies) Having an impaired sense of smell Tobacco use Presence of psychological symptoms within the past 6 months (as reported by the mother)

Design outcomes

Primary

MeasureTime frame
Incidence of nausea and vomiting. Timepoint: Four days after begining of intervention. Method of measurement: PUQE_24 Scale.

Secondary

MeasureTime frame
Adverse events. Timepoint: During and four days after begining of intervention. Method of measurement: By a 5-item questionnaire.;Satisfaction. Timepoint: Four days after begining of intervention. Method of measurement: By a 3-item questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Razavi_Hossein_Abad

Tabriz University of Medical Sciences

frazavi1381@yahoo.com+98 41 3447 2966

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026